Trials / Recruiting
RecruitingNCT07264426
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- argenx · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aims of this study are to assess the real-world effectiveness of efgartigimod in treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), describe the "treatment journey" of participants with CIDP, and assess the utilization of health care services among adult participants with CIDP who initiate treatment with efgartigimod. As this is a noninterventional study, treatment choices and decisions will be left to the discretion of participants and their physicians, according to the standard of care. Each participant will be prospectively followed for up to 2 years from the date of initial administration of efgartigimod.
Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- CIDP
- CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Efgartigimod PH20 SC | Efgartigimod treatment per country-specific label for the treatment of CIDP |
Timeline
- Start date
- 2025-08-11
- Primary completion
- 2029-10-01
- Completion
- 2029-10-01
- First posted
- 2025-12-04
- Last updated
- 2026-03-11
Locations
19 sites across 2 countries: United States, Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07264426. Inclusion in this directory is not an endorsement.